CPA
IDXX icon

Capital Performance Advisors’s Idexx Laboratories IDXX Stock Holding History

Capital Performance Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-416
Closed -$234K – 398
2026
Q1 		$234K Buy
416
+46
+12% +$29.5K 0.02% 395
2025
Q4 		$250K Buy
+370
New +$252K 0.02% 356
2024
Q4 		– Sell
-27
Closed -$13.6K – 1323
2024
Q3 		$13.6K Buy
+27
New +$13.1K ﹤0.01% 718

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Capital Performance Advisors's IDXX Position: Q2 2026 in Review

Capital Performance Advisors sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 416 shares — an estimated $234K sold.

Capital Performance Advisors first reported a position in IDXX in Q3 2024 and held it in 3 quarters. The position peaked at $250K in Q4 2025. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Capital Performance Advisors reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
  • Capital Performance Advisors sold 416 Idexx Laboratories shares in Q2 2026, an estimated $234K.
  • Capital Performance Advisors first reported a position in Idexx Laboratories in Q3 2024 and held it in 3 quarters.
  • Capital Performance Advisors's Idexx Laboratories position peaked at $250K in Q4 2025.
  • 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.